Irene is a biopharmaceutical business consultant with demonstrated success in building global commercialization plans to drive product launches and life cycle strategies. An experienced brand strategist, Irene has championed products across therapeutic areas, directly launching three blockbuster brands in multiple sclerosis and consulting on the plans of later market entrants.

Irene began her career at Johnson & Johnson, then joined Biogen for the launch of Avonex, to establish their MS Franchise strategy, and to lead the US team in the launch and relaunch of Tysabri. Wanting to work on an early-stage program, Irene joined Novartis Pharmaceutical in Switzerland for the start of the Gilenya development program, globally launching the first oral treatment for MS. With recognized strengths in early-stage development, launch readiness, and go-to-market plans, Irene continues to provide value and insights on commercial strategy.

Project deliverables:

• Comprehensive brand plans with detailed tactical plans
• Business plans and market opportunity assessments that define the value proposition and ideal target product profile
• Identify best commercial practices by functional area, including launch team detailed project plans
• Defined patient services model and “HUB” structure required for a successful patient journey